A breakthrough liquid biopsy platform that uses long-read nanopore sequencing to analyze non-coding cell-free RNA for the highly sensitive detection of early-stage cancer and precancerous conditions. The technology enables the discovery of novel drug targets for disease interception and is compatible with portable, handheld sequencing devices for flexible clinical and research applications.
This liquid biopsy platform leverages direct, long-read nanopore sequencing of full-length cell-free RNA (cfRNA) from plasma to detect early-stage cancer and precancerous conditions. By targeting non-coding "dark matter" RNA—genetic material often overlooked by standard sequencing—the platform provides high sensitivity and specificity for early-stage disease detection, where biological signals are typically low. Beyond diagnostics, the technology identifies dysregulated molecular pathways, enabling the discovery of novel drug targets for therapeutic interception.
The technology is currently at TRL 5. It has moved beyond conceptualization to laboratory validation and demonstration, with success in identifying novel biomarkers and classifying patient samples (healthy, precancerous, and cancer) in research cohorts. The platform is now entering a phase of expanded assessment in larger patient populations through a strategic research partnership with Oxford Nanopore Technologies to advance clinical utility.
UC Santa Cruz is a public land‑grant research university in Santa Cruz, California, recognized for interdisciplinary collaboration within the University of California system. Its Silicon Valley campus in Santa Clara places programs and engagement in the heart of the tech cluster. On the main campus and at the Westside Research Park, shared facilities and collaborative spaces connect faculty with companies for joint development and translation. Research is supported by competitive federal agencies, including NSF, NIH, DOE, and NASA, and strengthened by longstanding collaboration with NASA Ames. Industry partnership and tech transfer—through the Innovation & Business Engagement Hub, the Industry Alliances & Technology Commercialization office, and UC’s systemwide network—streamline IP, sponsored research, and startups.